VolitionRx Receives International ISO Certification for Quality Management System of its NuQ(R) Blood Tests
VolitionRx Releases Annual Shareholder Update Letter
VolitionRx Announces Dr. Jason Terrell's Transition to Full-Time Status as Chief Medical Officer and Head of U.S. Operations
VolitionRx Granted Its Third U.S. Patent
VolitionRx Demonstrates More Than 90% Accuracy for Colorectal Cancer NuQ(R) Blood Test in Completed Prospective Study
VolitionRx to Present at LD Micro Conference on December 3 in Los Angeles
VolitionRx Demonstrates NuQ® Blood Test Detects Lung Cancers with more than 90% Accuracy
VolitionRx Granted Its Second U.S. Patent
VolitionRx to Present at Two Conferences in November
VolitionRx Announces Third Quarter 2015 Financial Results and Business Update
